Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Barry Uretsky to Cardiotonic Agents

This is a "connection" page, showing publications Barry Uretsky has written about Cardiotonic Agents.

 
Connection Strength
  
 
 
1.332
  
  1. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000 Aug 08; 102(6):611-6.
    View in: PubMed
    Score: 0.174
  2. Uretsky BF, Vallurupalli S. Is the Digitalis Leaf Still Withering? J Am Coll Cardiol. 2019 08 06; 74(5):628-630.
    View in: PubMed
    Score: 0.162
  3. Uretsky BF. Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Drugs Aging. 1995 Jul; 7(1):1-9.
    View in: PubMed
    Score: 0.122
  4. Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C, Uretsky BF, Poh KK, Tan HC, Fujise K. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther. 2011 Jun; 25(3):223-32.
    View in: PubMed
    Score: 0.092
  5. Huang MH, Wang HQ, Roeske WR, Birnbaum Y, Wu Y, Yang NP, Lin Y, Ye Y, McAdoo DJ, Hughes MG, Lick SD, Boor PJ, Lui CY, Uretsky BF. Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H376-84.
    View in: PubMed
    Score: 0.069
  6. Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol. 1986 Jul 01; 58(1):110-6.
    View in: PubMed
    Score: 0.065
  7. Uretsky BF. Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering? Postgrad Med J. 1986 Jun; 62(728):585-92.
    View in: PubMed
    Score: 0.065
  8. Uretsky BF, Valdes AM, Reddy PS. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Circulation. 1986 Mar; 73(3 Pt 2):III219-29.
    View in: PubMed
    Score: 0.064
  9. Uretsky BF, Seecof RM, Reddy PS. The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response. Can J Cardiol. 1986 Mar-Apr; 2(2):80-5.
    View in: PubMed
    Score: 0.064
  10. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther. 2006 Feb; 20(1):27-36.
    View in: PubMed
    Score: 0.064
  11. Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. J Am Coll Cardiol. 1985 Jun; 5(6):1414-21.
    View in: PubMed
    Score: 0.061
  12. Uretsky BF, Generalovich T, Reddy PS, Salerni R, Valdes AM, Spangenberg RB, Lang JF, Okerholm RA. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. Am J Cardiol. 1984 Aug 01; 54(3):357-62.
    View in: PubMed
    Score: 0.057
  13. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002 Mar 20; 39(6):946-53.
    View in: PubMed
    Score: 0.049
  14. O'Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 Jul; 138(1 Pt 1):78-86.
    View in: PubMed
    Score: 0.040
  15. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Patterson JH, Tomasko L, Packer M. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J. 1998 Mar; 135(3):389-97.
    View in: PubMed
    Score: 0.037
  16. Murali S, Uretsky BF, Reddy PS, Tokarczyk TR, Betschart AR. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J. 1991 Nov; 122(5):1375-81.
    View in: PubMed
    Score: 0.024
  17. Uretsky BF, Hua J. Combined intravenous pharmacotherapy in the treatment of patients with decompensated congestive heart failure. Am Heart J. 1991 Jun; 121(6 Pt 1):1879-86.
    View in: PubMed
    Score: 0.023
  18. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 1990 Sep; 82(3):774-80.
    View in: PubMed
    Score: 0.022
  19. Murali S, Uretsky BF, Betschart AR, Tokarczyk TR, Kolesar JA, Reddy PS. Differential hemodynamic effects of oral enoximone in severe congestive heart failure. Am J Cardiol. 1990 Feb 15; 65(7):515-9.
    View in: PubMed
    Score: 0.021
  20. Ye Y, Lin Y, Perez-Polo R, Huang MH, Hughes MG, McAdoo DJ, Manickavasagam S, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H813-8.
    View in: PubMed
    Score: 0.017
  21. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1960-8.
    View in: PubMed
    Score: 0.016
  22. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol. 1985 Mar; 248(3 Pt 2):H396-402.
    View in: PubMed
    Score: 0.015
  23. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997 Jul; 134(1):44-54.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.